Thus, future prospective longitudinal DLB-specific studies with autopsy-confirmation are needed to quantitatively compare the time course of amyloid and tau biomarkers and to consider potential DLB-specific cutoffs. This evidence concerns the gene MAPT and Lewy body dementia.